Economic burden of multiple sclerosis in the United States: A systematic literature reviewMarion Schauf, Daniel M. Hartung, Edward Li et al.|Journal of Managed Care & Specialty Pharmacy|2023Cited by 23
Budget Impact Analysis of Biosimilar Natalizumab in the USEdward Li, Daniel M. Hartung, Marion Schauf et al.|The American Journal of Managed Care|2024Cited by 4
A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology populationJeanine Flanigan, G.H. Lyman, Stephen Chaplin et al.|Journal of Medical Economics|2025Cited by 1
Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal OsteoporosisJeanine Flanigan, GH Lyman, Edward Li et al.|PharmacoEconomics - Open|2026Cited by 1